Published: Jul, 2018

The global osteoporosis drugs market is analyzed in a report by Transparency Market Research (TMR). The market is expected to grow due to the increasing geriatric population across the globe. The market for osteoporosis drugs is considered semi-consolidated as a handful of players hold a larger share in the market. As per the analysis, Novartis International AG, Eli Lilly and Company, Merck & Co. Inc., Pfizer Inc., and Amgen Inc. held 63% of the total market share. The availability of effective products by these companies has enabled them to establish a stronghold in the market. Companies providing generic drugs that have the same active pharmaceuticals ingredient (API) are significantly contributing in the osteoporosis drugs market. The companies producing generic drugs are Teva Pharmaceutical Industries Ltd., Novo Nordisk A/S, F. Hoffmann La Roche Ltd., and Actavis plc.

As per the analysis done by TMR, by drug class the bisphosphonates segment is the fastest growing segment in the osteoporosis drugs market during the forecast period. Geographically, North America is the leading the global osteoporosis drugs market, mainly due to increased number suffering from osteoporosis. Technological advancements and increasing awareness about the disease have also grown in this region. Increasing population in the Asia Pacific will also boost the demand for osteoporosis drugs market in the forecast period.

global-osteoporosis-drugs-market

Demand for Osteoporosis Drugs High Among Geriatric Population

Osteoporosis develops due to increasing pores in the bones. As the density in the bones increases. It makes the bones weaker and breakable.  Thus, increasing the risk of fractures, mainly in wrist, hip, and spinal vertebrae.  The development of bone tissues continues until late 30’s and then starts reducing rapidly. If it reduces rapidly, it results in osteoporosis. Osteoporosis is largely seen among females as compared to males, mainly after menopause that decreasing estrogen in the body.

Major factors surging the demand for osteoporosis drugs is the huge population suffering from this disease. According to the International Osteoporosis Foundation (IOF), the number of women suffering from osteoporosis has crossed more than billion. As a result, globally the demand for osteoporosis drugs is increasing rapidly at an alarming rate. In addition, with the development of new drugs classes that are generic in nature and reduces the side effects, as well as it also overcomes the threat of chronic drugs will also grow the global market for osteoporosis drugs.  

Changing Living Patterns May Increase Osteoporosis among Men

A study conducted by National Institutes of Health Osteoporosis and Related Bone Diseases, discloses that the changing living patterns and increasing consumption of alcohol, smoking, and sedentary lifestyle will raise the risk of osteoporosis in males. Thus, creating urgency to curb this disease and eventually increasing the demand for osteoporosis drugs market. The availability of a huge variety of pipeline drugs waiting for their approval in clinical trials will also boost the osteoporosis market. Abaloparatide, Romosozumab, ZP-PTH, Blosozumab, and ZP-034 are drugs yet to make their presence and curb the osteoporosis in the market. Furthermore, constant research and development by health organizations and companies to improvise newer techniques and develop alternative treatments is expected to grow the market in future. Additionally, increasing investments through various organizations is predicted to boost the global osteoporosis drugs market.

The information presented in this review is based on a TMR report, titled “Osteoporosis Drugs Market (By Drug Class Bisphosphonates, Calcitonin, RANK Ligand Inhibitors, Parathyroid Hormone Therapy (PTH), Selective Estrogen Receptor Modulators (SERMs), Others Estrogen therapy and vitamin D and Calcium) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends & Forecast 2014 - 2020.”

The Global Osteoporosis Drugs Market is segmented on the basis of:

  • Osteoporosis Drugs Market, by Drug Class
    • Bisphosphonates
    • Parathyroid Hormone Therapy (PTH) Drugs
    • Selective Estrogen Receptor Modulators (SERMs)
    • RANK Ligand Inhibitors
    • Calcitonin
    • Others (Vitamin D, Calcium)
    • Pipeline Analysis
  • Osteoporosis Drugs Market, by Geography
    • North America
    • Europe
    • Asia-Pacific
    • Rest of the World (RoW)

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com

.